非小细胞肺癌肝转移免疫治疗相关的研究进展
Research Progress Related to Immunotherapy for Liver Metastasis of Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.1361446, PDF,   
作者: 陈 杰, 张学文, 郑凯曼：青海大学研究生院，青海 西宁；姜 军*：青海大学附属医院肿瘤内科，青海 西宁
关键词: 非小细胞肺癌；肝转移；免疫治疗；联合治疗；Non-Small Cell Lung Cancer； Liver Metastasis； Immunization Therapy； Combined Therapy
摘要: NSCLC肝转移患者发病率相对较低，但死亡率较高，多在7个月内死亡。因此，为了改善患者的总生存期及预后，采取积极有效的治疗尤为重要。目前，常见的免疫治疗有免疫单药及免疫联合化学治疗、靶向治疗、放射治疗、手术治疗等，本文就免疫治疗相关研究进展方面进行阐述。
Abstract: The morbidity of patients with NSCLC liver metastasis is relatively low, but the mortality is high, most of them die within 7 months. Therefore, in order to improve the overall survival and prognosis of patients, it is particularly important to take active and effective treatment. At present, common immunotherapy includes immune monotherapy and immunocombined chemotherapy, targeted therapy, radiotherapy, surgical therapy. This article will discuss the progress of immunotherapy related research.
文章引用：陈杰, 张学文, 郑凯曼, 姜军. 非小细胞肺癌肝转移免疫治疗相关的研究进展[J]. 临床医学进展, 2023, 13(6): 10329-10334. https://doi.org/10.12677/ACM.2023.1361446

参考文献

[1] Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Friedlaender, A., et al. (2020) Targeted Therapies in Early Stage NSCLC: Hype or Hope? International Journal of Molecular Sciences, 21, Article No. 6329. [Google Scholar] [CrossRef] [PubMed]
[3] Li, J., Zhu, H., Sun, L., Xu, W. and Wang, X. (2019) Prognostic Value of Site-Specific Metastases in Lung Cancer: A Population Based Study. Journal of Cancer, 10, 3079-3086. [Google Scholar] [CrossRef] [PubMed]
[4] Yu, J., et al. (2021) Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage-Mediated T Cell Elimination. Nature Medicine, 27, 152-164. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications, 42, 937-970. [Google Scholar] [CrossRef] [PubMed]
[6] Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249. [Google Scholar] [CrossRef] [PubMed]
[7] Borghaei, H., et al. (2021) Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733. [Google Scholar] [CrossRef] 
[8] Borghaei, H., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 1627-1639. [Google Scholar] [CrossRef] 
[9] Brahmer, J., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 123-135. [Google Scholar] [CrossRef] 
[10] Xie, M., et al. (2022) The Efficacy of PD-1/PD-L1 Inhibitors in Pa-tients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study. Cancers, 14, Article No. 4333. [Google Scholar] [CrossRef] [PubMed]
[11] Hong, L., et al. (2023) Efficacy and Clinicogenomic Correlates of Response to Immune Checkpoint Inhibitors Alone or with Chemotherapy in Non-Small Cell Lung Cancer. Nature Communications, 14, Article No. 695. [Google Scholar] [CrossRef] [PubMed]
[12] Li, L., et al. (2020) Indirect Comparison betweenImmunotherapy Alone and Immunotherapy plus Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Systematic Review. BMJ Open, 10, e034010. [Google Scholar] [CrossRef] [PubMed]
[13] Choi, M.G., et al. (2021) Different Prognostic Implications of Hepatic Metastasis According to Front-Line Treatment in Non-Small Cell Lung Cancer: A Real-World Retrospective Study. Translational Lung Cancer Research, 10, 2551-2561. [Google Scholar] [CrossRef] [PubMed]
[14] Zhu, Z., et al. (2022) International Consensus on Radiotherapy in Meta-static Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 11, 1763-1795. [Google Scholar] [CrossRef] [PubMed]
[15] Corrao, G., et al. (2020) Stereotatic Radiotherapy in Metastatic Non-Small Cell Lung Cancer: Combining Immunotherapy and Radiotherapy with a Focus on Liver Metastases. Lung Cancer, 142, 70-79. [Google Scholar] [CrossRef] [PubMed]
[16] Spigel, D.R., et al. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311. [Google Scholar] [CrossRef] 
[17] Wujanto, C., et al. (2019) Stereotactic Body Radiotherapy for Oli-gometastatic Disease in Non-Small Cell Lung Cancer. Frontiers in Oncology, 9, Article 1219. [Google Scholar] [CrossRef] [PubMed]
[18] Vanneste, B.G.L., Van Limbergen, E.J., Reynders, K. and De Ruysscher, D. (2021) An Overview of the Published and Running Randomized Phase 3 Clinical Results of Radiotherapy in Combination with Immunotherapy. Translational Lung Cancer Research, 10, 2048-2058. [Google Scholar] [CrossRef] [PubMed]
[19] Ettinger, D.S., et al. (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 497-530. [Google Scholar] [CrossRef] [PubMed]
[20] Arbour, K.C. and Riely, G.J. (2019) Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA, 322, 764-774. [Google Scholar] [CrossRef] [PubMed]
[21] Ren, S., Xiong, X., You, H., Shen, J. and Zhou, P. (2021) The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 12, Article 689132. [Google Scholar] [CrossRef] [PubMed]
[22] Moya-Horno, I., Viteri, S., Karachaliou, N. and Rosell, R. (2018) Combination of Immunotherapy with Targeted Therapies in Advanced Non-Small Cell Lung Cancer (NSCLC). Thera-peutic Advances in Medical Oncology, 10. [Google Scholar] [CrossRef] [PubMed]
[23] Reck, M., et al. (2019) Atezolizumab plus Bevacizumab and Chemotherapy in Non-Small-Cell Lung Cancer (IMpower150): Key Subgroup Analyses of Patients with EGFR Muta-tions or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. The Lancet Respiratory Medicine, 7, 387-401. [Google Scholar] [CrossRef] 
[24] Herbst, R.S., et al. (2016) Pembrolizumab versus Docet-axel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled. Lancet, 387, 1540-1550. [Google Scholar] [CrossRef] 
[25] Chae, Y.K., et al. (2018) Current Landscape and Future of Dual Anti-CTLA4 and PD-1/PD-L1 Blockade Immunotherapy in Cancer; Lessons Learned from Clinical Trials with Melanoma and Non-Small Cell Lung Cancer (NSCLC). Journal for ImmunoTherapy of Cancer, 6, Article No. 39. [Google Scholar] [CrossRef] [PubMed]
[26] Hellmann, M.D., et al. (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 378, 2093-2104. [Google Scholar] [CrossRef] 
[27] Antonia, S., et al. (2016) Safety and Antitumour Activity of Dur-valumab plus Tremelimumab in Non-Small Cell Lung Cancer: A Multicentre, Phase 1b Study. The Lancet Oncology, 17, 299-308. [Google Scholar] [CrossRef] 
[28] Hellmann, M.D., et al. (2017) Nivolumab plus Ipilimumab as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer (CheckMate 012): Results of an Open-Label, Phase 1, Multicohort Study. The Lancet Oncology, 18, 31-41. [Google Scholar] [CrossRef] 
[29] Paz-Ares, L.G., et al. (2022) First-Line Nivolumab plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes from the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17, 289-308. [Google Scholar] [CrossRef] [PubMed]
[30] Puri, S. and Shafique, M. (2020) Combination Checkpoint Inhibi-tors for Treatment of Non-Small-Cell Lung Cancer: An Update on Dual Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies. Drugs in Context, 9, Article ID: 2019-9-2. [Google Scholar] [CrossRef] [PubMed]
[31] Brito, A.B.C., Camandaroba, M.P.G. and de Lima, V.C.C. (2021) An-ti-PD1 versus Anti-PD-L1 Immunotherapy in First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Sys-tematic Review and Meta-Analysis. Thoracic Cancer, 12, 1058-1066. [Google Scholar] [CrossRef] [PubMed]
[32] Qin, B.-D., et al. (2020) The Effect of Liver Metastasis on Efficacy of Immunotherapy plus Chemotherapy in Advanced Lung Cancer. Critical Reviews in Oncology/Hematology, 147, Arti-cle ID: 102893. [Google Scholar] [CrossRef] [PubMed]
[33] Liu, J., Li, C., Seery, S., Yu, J. and Meng, X. (2020) Identi-fying Optimal First-Line Interventions for Advanced Non-Small Cell Lung Carcinoma According to PD-L1 Expression: A Systematic Review and Network Meta-Analysis. OncoImmunology, 9, Article 1746112. [Google Scholar] [CrossRef] 
[34] Liang, H., et al. (2020) Feasibility and Safety of PD-1/L1 Inhibitors for Non-Small Cell Lung Cancer in Front-Line Treatment: A Bayesian Network Meta-Analysis. Translational Lung Cancer Research, 9, 188-203. [Google Scholar] [CrossRef] [PubMed]
[35] Ishige, F., et al. (2018) Hepatectomy for Oligo-Recurrence of Non-Small Cell Lung Cancer in the Liver. International Journal of Clinical Oncology, 23, 647-651. [Google Scholar] [CrossRef] [PubMed]
[36] Hakoda, H., et al. (2019) Hepatectomy for Rapidly Growing Sol-itary Liver Metastasis from Non-Small Cell Lung Cancer: A Case Report. Surgical Case Reports, 5, Article No. 71. [Google Scholar] [CrossRef] [PubMed]
[37] Nagashima, A., Abe, Y., Yamada, S., Nakagawa, M. and Yoshi-matsu, T. (2004) Long-Term Survival after Surgical Resection of Liver Metastasis from Lung Cancer. The Japanese Journal of Thoracic and Cardiovascular Surgery, 52, 311-313. [Google Scholar] [CrossRef] [PubMed]
[38] Ileana, E., Greillier, L., Moutardier, V. and Barlesi, F. (2010) Sur-gical Resection of Liver Non-Small Cell Lung Cancer Metastasis: A Dual Weapon? Lung Cancer, 70, 221-222. [Google Scholar] [CrossRef] [PubMed]
[39] Takahashi, H. and Berber, E. (2020) Role of Thermal Abla-tion in the Management of Colorectal Liver Metastasis. Hepatobiliary Surgery and Nutrition, 9, 49-58. [Google Scholar] [CrossRef] [PubMed]
[40] Martins, F., et al. (2019) Adverse Effects of Im-mune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nature Reviews Clinical Oncology, 16, 563-580. [Google Scholar] [CrossRef] [PubMed]

为你推荐